Drug intelligence / Profile preview

ARR-173

Development stage: Preclinical
Lead developer: ArriVent BioPharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ARR-173 is an antibody-drug conjugate (ADC) being developed by ArriVent BioPharma in collaboration with Alphamab Oncology for the treatment of solid tumors. The program leverages Alphamab's proprietary linker-payload platform and site-specific glycan-conjugation technology to identify and develop novel ADC candidates. ArriVent holds exclusive worldwide rights for the development and commercialization of ARR-173 outside of the Greater China region. As of the current reporting, the specific biological target, cytotoxic payload, and clinical development stage have not been publicly disclosed.

Beyond the preview

Go deeper on ARR-173.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARR-173.

Explore the full profile